Neotigason (acitretin)

Information for patients

Pregnancy Prevention Programme

Neotigason capsules contain the active ingredient acitretin, which is belongs to a group of medicines known as ‘retinoids’.

This medicine can seriously harm an unborn baby (the medicine is said to be ‘teratogenic’). You must not take Neotigason if you are pregnant. If there is any chance you could become pregnant, you must follow the precautions of the ”Pregnancy prevention programme” outlined in the package leaflet and the patient reminder card.

Teva provides pregnancy prevention programme (PPP) materials for patients treated with Neotigason (acitretin) 10 mg and 25 mg hard capsules:

Patient reminder card


Further information (such as how to take Neotigason, special warnings and possible side effects) is included in the package leaflet, which is supplied in each pack of Neotigason. Please read the leaflet carefully.

An electronic copy of the package leaflet can be accessed from the Health Products Regulatory Authority (HPRA) website here

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

You can report side effects directly via the national reporting system: HPRA Pharmacovigilance, Earlsfort Terrace, Dublin, Ireland. Tel: 01 6764971; Fax: 01 6762517; Email: ; Website:

You can also report side effects directly to Teva via our online form

If you have any queries please contact your doctor or pharmacist or Teva's Medical Information team on +44 207 540 7117 or email

Date of preparation: January 2023
Reference: COB-IE-NP-00043